首页 > 最新文献

Toxicologic Pathology最新文献

英文 中文
Session 4: mRNA and Self-Amplifying RNA (saRNA): Opportunities for Disease Prevention and Therapy. 会议 4:mRNA 和自扩增 RNA(saRNA):疾病预防和治疗的机遇。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1177/01926233241298572
Rani S Sellers, Lila Ramaiah, Sue-Jean Hong, Prashant Nambiar, Eric Jacquinet, Shan Naidu

The unprecedented speed of developing vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has propelled mRNA technologies into the public eye. The versatility of mRNA technology, often referred to as "plug and play," offers immense promise for rapidly updating vaccines to address newer variants of respiratory diseases and combat emerging infectious diseases and lethal pathogens, such as the Ebolavirus. However, the potential applications of mRNA technology extend well beyond prophylactic vaccines. This session explored the two primary mRNA platforms: nonreplicating mRNA and self-amplifying mRNA (variably referred to as saRNA, samRNA, or SAM). Presentation topics were on current research efforts aimed at broadening the applications of mRNA modalities beyond vaccines. Topics included opportunities for delivering mRNA via intra-tumoral and inhalational routes, immunological and systemic inflammatory responses elicited by these modalities, and regulatory considerations involved in the development and licensing of these technologies.

针对造成 COVID-19 大流行的严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)的疫苗开发速度前所未有,这使 mRNA 技术成为公众关注的焦点。mRNA 技术通常被称为 "即插即用",它的多功能性为快速更新疫苗以应对呼吸道疾病的新变种以及对抗新出现的传染病和致命病原体(如埃博拉病毒)带来了巨大的希望。然而,mRNA 技术的潜在应用远不止于预防性疫苗。本次会议探讨了两种主要的 mRNA 平台:非复制 mRNA 和自扩增 mRNA(又称 saRNA、samRNA 或 SAM)。演讲主题是当前旨在将 mRNA 模式的应用范围扩大到疫苗之外的研究工作。主题包括通过瘤内和吸入途径递送mRNA的机会、这些模式引起的免疫和全身炎症反应,以及这些技术的开发和许可所涉及的监管考虑因素。
{"title":"Session 4: mRNA and Self-Amplifying RNA (saRNA): Opportunities for Disease Prevention and Therapy.","authors":"Rani S Sellers, Lila Ramaiah, Sue-Jean Hong, Prashant Nambiar, Eric Jacquinet, Shan Naidu","doi":"10.1177/01926233241298572","DOIUrl":"10.1177/01926233241298572","url":null,"abstract":"<p><p>The unprecedented speed of developing vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, has propelled mRNA technologies into the public eye. The versatility of mRNA technology, often referred to as \"plug and play,\" offers immense promise for rapidly updating vaccines to address newer variants of respiratory diseases and combat emerging infectious diseases and lethal pathogens, such as the Ebolavirus. However, the potential applications of mRNA technology extend well beyond prophylactic vaccines. This session explored the two primary mRNA platforms: nonreplicating mRNA and self-amplifying mRNA (variably referred to as saRNA, samRNA, or SAM). Presentation topics were on current research efforts aimed at broadening the applications of mRNA modalities beyond vaccines. Topics included opportunities for delivering mRNA via intra-tumoral and inhalational routes, immunological and systemic inflammatory responses elicited by these modalities, and regulatory considerations involved in the development and licensing of these technologies.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"545-552"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors. 重组腺相关病毒基因疗法载体的全身毒性。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1177/01926233241298892
Basel T Assaf

Recombinant adeno-associated virus (rAAV) vectors have emerged as a promising tool for gene therapy. However, the systemic administration of rAAV vectors is not without risks, particularly for dose levels >1 × 1014 viral genome per kilogram of body weight (vg/kg). rAAV-associated toxicities can variably manifest either acutely or in a delayed manner. Acute toxicities often present shortly after administration and can include severe immune responses, hepatotoxicity, and thrombotic microangiopathy (TMA). Delayed toxicities, on the other hand, may emerge weeks to months post-treatment, potentially involving chronic liver damage or prolonged immune activation. Thrombotic microangiopathy is often associated with complement activation and endothelial damage. The activation of the complement system can additionally trigger a cascade of inflammatory responses, exacerbating systemic toxicity. While many of these toxicities are reversible with appropriate medical intervention, there have been instances where the adverse effects were severe enough to lead to fatalities. Both human and animal studies have reported these adverse effects, highlighting the critical importance of thorough preclinical testing. However, a differential toxicity profile associated with systemic AAV administration exists between humans and nonhuman primates (NHPs), in which certain toxicities reported in humans are yet to be observed in NHPs, and vice versa. This review aims to explore the recent literature on systemic rAAV toxicities, focusing on dose levels, the role of the complement activation pathway, endothelial injury, TMA, hepatotoxicity, and the bidirectional translational safety profiles from both human and animal studies.

重组腺相关病毒(rAAV)载体已成为一种前景广阔的基因治疗工具。然而,rAAV 载体的全身给药并非没有风险,尤其是当剂量水平大于每公斤体重 1 × 1014 病毒基因组(vg/kg)时。急性毒性通常在用药后不久出现,可包括严重的免疫反应、肝毒性和血栓性微血管病(TMA)。而延迟毒性则可能在治疗后数周至数月出现,可能涉及慢性肝损伤或长期免疫激活。血栓性微血管病通常与补体激活和内皮损伤有关。补体系统的激活还会引发一系列炎症反应,加剧全身毒性。虽然这些毒性中的许多在适当的医疗干预下是可逆的,但也有不良反应严重到导致死亡的情况。人类和动物研究都曾报告过这些不良反应,这凸显了全面临床前试验的极端重要性。然而,人与非人灵长类动物(NHPs)之间存在着与全身性 AAV 给药相关的不同毒性特征,其中某些在人身上报告的毒性尚未在 NHPs 身上观察到,反之亦然。本综述旨在探讨有关全身性 rAAV 毒性的最新文献,重点关注剂量水平、补体激活途径的作用、内皮损伤、TMA、肝毒性以及人类和动物研究的双向转化安全性概况。
{"title":"Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors.","authors":"Basel T Assaf","doi":"10.1177/01926233241298892","DOIUrl":"10.1177/01926233241298892","url":null,"abstract":"<p><p>Recombinant adeno-associated virus (rAAV) vectors have emerged as a promising tool for gene therapy. However, the systemic administration of rAAV vectors is not without risks, particularly for dose levels >1 × 10<sup>14</sup> viral genome per kilogram of body weight (vg/kg). rAAV-associated toxicities can variably manifest either acutely or in a delayed manner. Acute toxicities often present shortly after administration and can include severe immune responses, hepatotoxicity, and thrombotic microangiopathy (TMA). Delayed toxicities, on the other hand, may emerge weeks to months post-treatment, potentially involving chronic liver damage or prolonged immune activation. Thrombotic microangiopathy is often associated with complement activation and endothelial damage. The activation of the complement system can additionally trigger a cascade of inflammatory responses, exacerbating systemic toxicity. While many of these toxicities are reversible with appropriate medical intervention, there have been instances where the adverse effects were severe enough to lead to fatalities. Both human and animal studies have reported these adverse effects, highlighting the critical importance of thorough preclinical testing. However, a differential toxicity profile associated with systemic AAV administration exists between humans and nonhuman primates (NHPs), in which certain toxicities reported in humans are yet to be observed in NHPs, and vice versa. This review aims to explore the recent literature on systemic rAAV toxicities, focusing on dose levels, the role of the complement activation pathway, endothelial injury, TMA, hepatotoxicity, and the bidirectional translational safety profiles from both human and animal studies.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"523-530"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proceedings of the 2024 Division of Translational Toxicology Satellite Symposium. 2024年转化毒理学卫星研讨会论文集。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-12-01 Epub Date: 2024-12-11 DOI: 10.1177/01926233241298895
Erin M Quist, Shambhunath Choudhary, Typhaine Lejeune, Emily Mackey, Priyanka Thakur, Kristen Hobbie, Amanda Duggan

The 2024 annual Division of Translational Toxicology (DTT) Satellite Symposium, entitled "Pathology Potpourri," was held in Baltimore, Maryland, at the Society of Toxicologic Pathology's 42nd annual meeting. The goal of this symposium was to present and discuss challenging diagnostic pathology and/or nomenclature issues. This article presents summaries of the speakers' talks along with select images that were used by the audience for voting and discussion. Various lesions and topics covered during the symposium included induced nonneoplastic lesions in the mouse kidney, induced and spontaneous neoplastic lesions in the mouse lung, infectious and proliferative lesions in nonhuman primates, an interesting inflammatory lesion in a transgenic mouse strain, and a lesson on artifact recognition.

2024年,在马里兰州巴尔的摩市举行的第42届毒理学病理学会年会上,一年一度的转化毒理学(DTT)卫星研讨会题为“病理学杂烩”。本次研讨会的目的是提出和讨论具有挑战性的诊断病理学和/或命名问题。本文介绍了演讲者的演讲摘要以及观众用于投票和讨论的精选图像。研讨会期间涉及的各种病变和主题包括小鼠肾脏的诱导非肿瘤性病变,小鼠肺部的诱导和自发肿瘤性病变,非人灵长类动物的感染性和增殖性病变,转基因小鼠品系的有趣炎症病变,以及人工识别的课程。
{"title":"Proceedings of the 2024 Division of Translational Toxicology Satellite Symposium.","authors":"Erin M Quist, Shambhunath Choudhary, Typhaine Lejeune, Emily Mackey, Priyanka Thakur, Kristen Hobbie, Amanda Duggan","doi":"10.1177/01926233241298895","DOIUrl":"10.1177/01926233241298895","url":null,"abstract":"<p><p>The 2024 annual Division of Translational Toxicology (DTT) Satellite Symposium, entitled \"Pathology Potpourri,\" was held in Baltimore, Maryland, at the Society of Toxicologic Pathology's 42nd annual meeting. The goal of this symposium was to present and discuss challenging diagnostic pathology and/or nomenclature issues. This article presents summaries of the speakers' talks along with select images that were used by the audience for voting and discussion. Various lesions and topics covered during the symposium included induced nonneoplastic lesions in the mouse kidney, induced and spontaneous neoplastic lesions in the mouse lung, infectious and proliferative lesions in nonhuman primates, an interesting inflammatory lesion in a transgenic mouse strain, and a lesson on artifact recognition.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"460-488"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Neuropathology Evaluation in the Nonclinical Assessment of Seizure Liability. 神经病理学评估在癫痫发作责任非临床评估中的作用。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-12-01 Epub Date: 2024-12-05 DOI: 10.1177/01926233241300065
Katie Sokolowski, Judy Liu, Marcus S Delatte, Simon Authier, Owen McMaster, Brad Bolon

Test article (TA)-induced seizures represent a major safety concern in drug development. Seizures (altered brain wave [electrophysiological] patterns) present clinically as abnormal consciousness with or without tonic/clonic convulsions (where "tonic" = stiffening and "clonic" = involuntary rhythmical movements). Neuropathological findings following seizures may be detected using many methods. Neuro-imaging may show a structural abnormality underlying seizures, such as focal cortical dysplasia or hippocampal sclerosis in patients with chronic epilepsy. Neural cell type-specific biomarkers in blood or cerebrospinal fluid may highlight neuronal damage and/or glial reactions but are not specific indicators of seizures while serum electrolyte and glucose imbalances may induce seizures. Gross observations and brain weights generally are unaffected by TAs with seizurogenic potential, but microscopic evaluation may reveal seizure-related neuron death in some brain regions (especially neocortex, hippocampus, and/or cerebellum). Current globally accepted best practices for neural sampling in nonclinical general toxicity studies provide a suitable screen for brain regions that are known sites of electrical disruption and/or display seizure-induced neural damage. Conventional nonclinical studies can afford an indication that a TA has a potential seizure liability (via in-life signs and/or microscopic evidence of neuron necrosis), but confirmation requires measuring brain electrical (electroencephalographic) activity in a nonclinical study.

试验品(TA)诱发的癫痫发作是药物开发中一个主要的安全问题。癫痫发作(脑电波[电生理]模式改变)在临床上表现为意识异常,伴有或不伴有强直/阵挛性抽搐(强直=僵硬,阵挛=不自主的有节奏的运动)。癫痫发作后的神经病理结果可以用多种方法检测。神经影像学可能显示癫痫发作的结构异常,如慢性癫痫患者的局灶性皮质发育不良或海马硬化。血液或脑脊液中神经细胞类型特异性生物标志物可能突出神经元损伤和/或神经胶质反应,但不是癫痫发作的特异性指标,而血清电解质和葡萄糖失衡可能诱发癫痫发作。大体观察和脑重量通常不受具有癫痫致尿潜能的TAs的影响,但显微镜下的评估可能显示某些脑区(特别是新皮质、海马和/或小脑)与癫痫相关的神经元死亡。目前全球公认的非临床一般毒性研究中神经采样的最佳实践为已知的电中断和/或显示癫痫诱发的神经损伤的脑区域提供了合适的筛选。传统的非临床研究可以提供TA有潜在发作危险的指示(通过生命体征和/或神经元坏死的显微证据),但确认需要在非临床研究中测量脑电(脑电图)活动。
{"title":"The Role of Neuropathology Evaluation in the Nonclinical Assessment of Seizure Liability.","authors":"Katie Sokolowski, Judy Liu, Marcus S Delatte, Simon Authier, Owen McMaster, Brad Bolon","doi":"10.1177/01926233241300065","DOIUrl":"10.1177/01926233241300065","url":null,"abstract":"<p><p>Test article (TA)-induced seizures represent a major safety concern in drug development. Seizures (altered brain wave [electrophysiological] patterns) present clinically as abnormal consciousness with or without tonic/clonic convulsions (where \"tonic\" = stiffening and \"clonic\" = involuntary rhythmical movements). Neuropathological findings following seizures may be detected using many methods. Neuro-imaging may show a structural abnormality underlying seizures, such as focal cortical dysplasia or hippocampal sclerosis in patients with chronic epilepsy. Neural cell type-specific biomarkers in blood or cerebrospinal fluid may highlight neuronal damage and/or glial reactions but are not specific indicators of seizures while serum electrolyte and glucose imbalances may induce seizures. Gross observations and brain weights generally are unaffected by TAs with seizurogenic potential, but microscopic evaluation may reveal seizure-related neuron death in some brain regions (especially neocortex, hippocampus, and/or cerebellum). Current globally accepted best practices for neural sampling in nonclinical general toxicity studies provide a suitable screen for brain regions that are known sites of electrical disruption and/or display seizure-induced neural damage. Conventional nonclinical studies can afford an indication that a TA has a potential seizure liability (via in-life signs and/or microscopic evidence of neuron necrosis), but confirmation requires measuring brain electrical (electroencephalographic) activity in a nonclinical study.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"566-573"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies. 基于腺相关病毒(AAV)的视网膜基因治疗的非临床发展的病理发现和生活相关因素
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-12-01 DOI: 10.1177/01926233241307641
Helen S Booler, Typhaine Lejeune, Oliver Turner, Chandra Saravanan, Joshua T Bartoe, Brad Bolon

Adeno-associated virus (AAV)-based vectors are the most frequently used platform for retinal gene therapy. Initially explored for the treatment of loss-of-function mutations underpinning many inherited retinal diseases, AAV-based ocular gene therapies are increasingly used to transduce endogenous cells to produce therapeutic proteins, thus producing site-specific biofactories. Relatively invasive ocular routes of administration (ROA) mean prominent procedure-related in-life, and histopathological findings may be observed with some regularity. Test article-related findings may vary with the ROA and cell populations transduced, with retinal pigmented epithelium (RPE) changes prominent (ranging from pigment alteration through degeneration, with or without associated degeneration of the overlying retina) with subretinal ROA, and more anterior changes (iris, ciliary body) generally observed with the intravitreal ROA. Ocular inflammation is the most frequent finding that occurs nonclinically and in patients, and is particularly pronounced with intravitreal administration. Extraocular findings may be observed in extraocular muscles, regional ganglia, or central visual pathways with multiple ocular ROA. Work is still needed to understand the mechanisms underpinning many of these ocular and extraocular findings. Emerging patient data is helping to clarify both the potential for translating nonclinical findings to predict possible human responses and the applicability of nonclinical biomonitoring methods to the clinical setting.

基于腺相关病毒(AAV)的载体是视网膜基因治疗最常用的平台。基于aav的眼部基因疗法最初用于治疗许多遗传性视网膜疾病的功能丧失突变,现在越来越多地用于转导内源性细胞产生治疗性蛋白,从而产生位点特异性生物工厂。相对侵入性的眼部给药途径(ROA)意味着在生活中与手术相关的突出,组织病理学结果可能具有一定的规律性。测试文章相关的结果可能因ROA和细胞群的转导而异,视网膜色素上皮(RPE)的变化(从色素改变到变性,伴有或不伴有上覆视网膜变性)与视网膜下ROA显著,而更多的前部变化(虹膜、睫状体)通常观察到玻璃体内ROA。眼部炎症是最常见的发现,发生在非临床和患者,并在玻璃体内给药特别明显。眼外病变可见于眼外肌、区域神经节或多发眼ROA的中央视觉通路。我们还需要进一步了解这些眼部和眼外发现背后的机制。新出现的患者数据有助于阐明将非临床发现转化为预测可能的人类反应的潜力,以及非临床生物监测方法在临床环境中的适用性。
{"title":"Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies.","authors":"Helen S Booler, Typhaine Lejeune, Oliver Turner, Chandra Saravanan, Joshua T Bartoe, Brad Bolon","doi":"10.1177/01926233241307641","DOIUrl":"https://doi.org/10.1177/01926233241307641","url":null,"abstract":"<p><p>Adeno-associated virus (AAV)-based vectors are the most frequently used platform for retinal gene therapy. Initially explored for the treatment of loss-of-function mutations underpinning many inherited retinal diseases, AAV-based ocular gene therapies are increasingly used to transduce endogenous cells to produce therapeutic proteins, thus producing site-specific biofactories. Relatively invasive ocular routes of administration (ROA) mean prominent procedure-related in-life, and histopathological findings may be observed with some regularity. Test article-related findings may vary with the ROA and cell populations transduced, with retinal pigmented epithelium (RPE) changes prominent (ranging from pigment alteration through degeneration, with or without associated degeneration of the overlying retina) with subretinal ROA, and more anterior changes (iris, ciliary body) generally observed with the intravitreal ROA. Ocular inflammation is the most frequent finding that occurs nonclinically and in patients, and is particularly pronounced with intravitreal administration. Extraocular findings may be observed in extraocular muscles, regional ganglia, or central visual pathways with multiple ocular ROA. Work is still needed to understand the mechanisms underpinning many of these ocular and extraocular findings. Emerging patient data is helping to clarify both the potential for translating nonclinical findings to predict possible human responses and the applicability of nonclinical biomonitoring methods to the clinical setting.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":"52 8","pages":"506-522"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pathologist's Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products. 过继细胞治疗产品的非临床安全性评估病理学家指南。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-12-01 Epub Date: 2024-12-06 DOI: 10.1177/01926233241298570
Alessandra Piersigilli, Vinicius S Carreira, Frédéric Gervais, Keith Mansfield, Brian E McIntosh, Ingrid Cornax

Through two decades of research and development, adoptive cell therapies (ACTs) have revolutionized treatment for hematologic malignancies. Many of the seven US Food and Drug Administration (FDA)-approved products are proven to be a curative last line of defense against said malignancies. The ACTs, known more commonly as chimeric antigen receptor (CAR) T-cells, utilize engineered lymphocytes to target and destroy cancer cells in a patient-specific, major histocompatibility complex (MHC)-independent manner, acting as "living drugs" that adapt to and surveil the body post-treatment. Despite their efficacy, CAR T-cell therapies present unique challenges in preclinical safety assessment. The safety and pharmacokinetics of CAR T-cells are influenced by numerous factors including donor and recipient characteristics, product design, and manufacturing processes that are not well-predicted by existing in vitro and in vivo preclinical safety models. The CAR therapy-mediated toxicities in clinical settings primarily arise from unintended targeting of non-tumor cells, potential tumorigenicity, and severe immune activation syndromes like cytokine release syndrome and immune effector cell-associated neurotoxicity. Addressing these issues necessitates a deep understanding of CAR target expression in normal tissues, inclusive of the spatial microanatomical distribution, off-target screening, and a deep understanding CAR cell manufacturing practices and immunopathology.

经过二十年的研究和发展,过继细胞疗法(ACTs)已经彻底改变了血液恶性肿瘤的治疗方法。在美国食品和药物管理局(FDA)批准的7种产品中,有许多已被证明是治疗上述恶性肿瘤的最后一道防线。act,通常被称为嵌合抗原受体(CAR) t细胞,利用工程化淋巴细胞以患者特异性的、不依赖于主要组织相容性复合体(MHC)的方式靶向并摧毁癌细胞,充当适应和监测治疗后身体的“活药物”。尽管有疗效,CAR - t细胞疗法在临床前安全性评估方面面临着独特的挑战。CAR - t细胞的安全性和药代动力学受到许多因素的影响,包括供体和受体特征、产品设计和制造工艺,这些因素无法通过现有的体外和体内临床前安全模型很好地预测。临床环境中CAR治疗介导的毒性主要来自非肿瘤细胞的意外靶向、潜在的致瘤性和严重的免疫激活综合征,如细胞因子释放综合征和免疫效应细胞相关的神经毒性。解决这些问题需要深入了解正常组织中的CAR靶表达,包括空间微观解剖分布,脱靶筛选,以及深入了解CAR细胞制造实践和免疫病理学。
{"title":"A Pathologist's Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products.","authors":"Alessandra Piersigilli, Vinicius S Carreira, Frédéric Gervais, Keith Mansfield, Brian E McIntosh, Ingrid Cornax","doi":"10.1177/01926233241298570","DOIUrl":"10.1177/01926233241298570","url":null,"abstract":"<p><p>Through two decades of research and development, adoptive cell therapies (ACTs) have revolutionized treatment for hematologic malignancies. Many of the seven US Food and Drug Administration (FDA)-approved products are proven to be a curative last line of defense against said malignancies. The ACTs, known more commonly as chimeric antigen receptor (CAR) T-cells, utilize engineered lymphocytes to target and destroy cancer cells in a patient-specific, major histocompatibility complex (MHC)-independent manner, acting as \"living drugs\" that adapt to and surveil the body post-treatment. Despite their efficacy, CAR T-cell therapies present unique challenges in preclinical safety assessment. The safety and pharmacokinetics of CAR T-cells are influenced by numerous factors including donor and recipient characteristics, product design, and manufacturing processes that are not well-predicted by existing in vitro and in vivo preclinical safety models. The CAR therapy-mediated toxicities in clinical settings primarily arise from unintended targeting of non-tumor cells, potential tumorigenicity, and severe immune activation syndromes like cytokine release syndrome and immune effector cell-associated neurotoxicity. Addressing these issues necessitates a deep understanding of CAR target expression in normal tissues, inclusive of the spatial microanatomical distribution, off-target screening, and a deep understanding CAR cell manufacturing practices and immunopathology.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"531-544"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virtual Control Groups in Non-clinical Toxicity Studies: Impacts on Toxicologic Clinical Pathology Data Interpretation. 非临床毒性研究中的虚拟对照组:对毒理学临床病理数据解释的影响。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-11-30 DOI: 10.1177/01926233241300310
Adeyemi O Adedeji, Adi Wasserkrug Naor

One of the emerging concepts on the reduction of animal use in non-clinical studies is the use of virtual control group (VCG) to replace concurrent control group (CCG). The VCG involves the generation of a control data from historical control data to match a specific study design. This review focuses on two recently published proof-of-concept (POC) studies conducted in rats. One major issue that was consistently seen across these POC studies was the non-reproducibility of some quantitative endpoints between the CCG and the VCG, with clinical pathology parameters being the most affected. The inconsistencies observed with the clinical pathology parameters when using VCGs may lead to: (1) misconception about the accuracy and sensitivity of traditional clinical pathology biomarkers and its implications on safety monitoring in the clinic; (2) inability to correctly identify and characterize organ dysfunctions; (3) interference with the weight-of-evidence approach used in identifying hazards in toxicologic clinical pathology and toxicology studies at large; and (4) wrong interpretations and data reproducibility issues. Other alternatives to reduce animal use in toxicology studies are also discussed including blood microsampling for toxicokinetics, scientifically justified use of recovery animals, and appropriate use and continuous investments in new alternative methods.

在非临床研究中减少动物使用的新兴概念之一是使用虚拟对照组(VCG)来代替并发对照组(CCG)。VCG包括从历史对照数据中生成对照数据,以匹配特定的研究设计。本文综述了最近发表的两项在大鼠中进行的概念验证(POC)研究。在这些POC研究中一致发现的一个主要问题是CCG和VCG之间的一些定量终点的不可重复性,其中临床病理参数受到的影响最大。使用vcg时观察到的与临床病理参数的不一致可能导致:(1)对传统临床病理生物标志物的准确性和敏感性及其对临床安全监测的影响的误解;(2)不能正确识别和描述器官功能障碍;(3)干扰用于确定毒理学临床病理学和毒理学研究中危害的证据权重法;(4)错误解释和数据可重复性问题。还讨论了减少毒理学研究中动物使用的其他替代方法,包括用于毒性动力学的血液微采样,科学合理地使用恢复动物,以及适当使用和持续投资新的替代方法。
{"title":"Virtual Control Groups in Non-clinical Toxicity Studies: Impacts on Toxicologic Clinical Pathology Data Interpretation.","authors":"Adeyemi O Adedeji, Adi Wasserkrug Naor","doi":"10.1177/01926233241300310","DOIUrl":"https://doi.org/10.1177/01926233241300310","url":null,"abstract":"<p><p>One of the emerging concepts on the reduction of animal use in non-clinical studies is the use of virtual control group (VCG) to replace concurrent control group (CCG). The VCG involves the generation of a control data from historical control data to match a specific study design. This review focuses on two recently published proof-of-concept (POC) studies conducted in rats. One major issue that was consistently seen across these POC studies was the non-reproducibility of some quantitative endpoints between the CCG and the VCG, with clinical pathology parameters being the most affected. The inconsistencies observed with the clinical pathology parameters when using VCGs may lead to: (1) misconception about the accuracy and sensitivity of traditional clinical pathology biomarkers and its implications on safety monitoring in the clinic; (2) inability to correctly identify and characterize organ dysfunctions; (3) interference with the weight-of-evidence approach used in identifying hazards in toxicologic clinical pathology and toxicology studies at large; and (4) wrong interpretations and data reproducibility issues. Other alternatives to reduce animal use in toxicology studies are also discussed including blood microsampling for toxicokinetics, scientifically justified use of recovery animals, and appropriate use and continuous investments in new alternative methods.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"1926233241300310"},"PeriodicalIF":1.4,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxicologic Pathology Forum*: Opinion on Assessing and Communicating Adversity for Implantable Medical Devices. 毒理病理学论坛*:关于评估和通报植入式医疗器械不良反应的意见。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-11-27 DOI: 10.1177/01926233241300313
L M Wancket, B Bolon, K A Funk, J C L Schuh

Medical devices are a product class encompassing many materials and intended uses. While adversity determination is a key part of nonclinical safety assessments, relatively little has been published about the unique challenges encountered when determining adversity for implantable medical devices. The current paper uses the Society of Toxicologic Pathology (STP)'s "Scientific and Regulatory Policy Committee Recommended ('Best') Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies," which were crafted for conventional bio/pharmaceutical products (small and large molecules, cell and gene therapies, etc), as a framework for making adversity decisions for medical devices. Some best principles are directly translatable to medical devices: (1) adversity indicates harm to the animal; (2) effects should be assessed on their merits without speculation regarding future or unmeasured implications; (3) adversity decisions apply only to the test species under the specific conditions of the nonclinical study; and (4) adversity decisions and supporting evidence should be clearly stated in reports. However, unique considerations also apply for evaluating implanted medical devices, including testing of multiple articles in the same animal and the unavoidable tissue trauma during device implantation. This opinion piece offers suggestions for applying previously published STP best practice recommendations for assigning adversity to implantable medical devices.

医疗器械是一类包含多种材料和预期用途的产品。虽然逆境判定是非临床安全性评估的关键部分,但有关植入式医疗器械逆境判定所遇到的独特挑战的文章相对较少。本文采用毒理学病理学会(STP)的 "科学与监管政策委员会推荐的('最佳')非临床研究中不良反应数据的确定、沟通和使用方法 "作为医疗器械不良反应决策的框架,该方法是针对传统生物/制药产品(小分子和大分子、细胞和基因疗法等)而制定的。一些最佳原则可直接应用于医疗器械:(1) 逆境表明对动物造成了伤害;(2) 应根据影响的是非曲直进行评估,而不应推测未来或未测量的影响;(3) 逆境决定仅适用于非临床研究特定条件下的试验物种;(4) 应在报告中明确说明逆境决定和支持证据。然而,评估植入式医疗器械也有其独特的考虑因素,包括在同一动物体内测试多种物品以及植入器械过程中不可避免的组织创伤。本意见书就如何应用之前发布的 STP 最佳实践建议为植入式医疗器械分配逆境提出了建议。
{"title":"Toxicologic Pathology Forum*: Opinion on Assessing and Communicating Adversity for Implantable Medical Devices.","authors":"L M Wancket, B Bolon, K A Funk, J C L Schuh","doi":"10.1177/01926233241300313","DOIUrl":"https://doi.org/10.1177/01926233241300313","url":null,"abstract":"<p><p>Medical devices are a product class encompassing many materials and intended uses. While adversity determination is a key part of nonclinical safety assessments, relatively little has been published about the unique challenges encountered when determining adversity for implantable medical devices. The current paper uses the Society of Toxicologic Pathology (STP)'s \"Scientific and Regulatory Policy Committee Recommended ('Best') Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies,\" which were crafted for conventional bio/pharmaceutical products (small and large molecules, cell and gene therapies, etc), as a framework for making adversity decisions for medical devices. Some best principles are directly translatable to medical devices: (1) adversity indicates harm to the animal; (2) effects should be assessed on their merits without speculation regarding future or unmeasured implications; (3) adversity decisions apply only to the test species under the specific conditions of the nonclinical study; and (4) adversity decisions and supporting evidence should be clearly stated in reports. However, unique considerations also apply for evaluating implanted medical devices, including testing of multiple articles in the same animal and the unavoidable tissue trauma during device implantation. This opinion piece offers suggestions for applying previously published STP best practice recommendations for assigning adversity to implantable medical devices.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"1926233241300313"},"PeriodicalIF":1.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opinion on the Importance of Sharing Toxicologic Pathology Data for Educational and/or Scientific Purposes. 关于为教育和/或科学目的共享毒理病理学数据的重要性的意见。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-11-18 DOI: 10.1177/01926233241296122
Eveline de Rijk, Phaedra Cole, Anna-Lena Frisk, Frederic Gervais, Joost Lensen, Barbara Lenz, Lars Mecklenburg, Flavia Pasello Dos Santos, Annette Romeike, Catherine Ross

Sharing pathology data is critical for educational and scientific purposes. Since most pharmaceutical or (agro)chemical companies outsource nonclinical safety assessment studies to contract research organizations (CROs), the pathology data of those studies are not owned by the investigator but is the legal property of the respective company sponsoring the work. Although some companies have installed policies that govern sharing of pathology data, many companies generally do not allow the external use of data by either the CRO-based study pathologist or the sponsor pathologist. Policies for governing the external use of data vary significantly. In this article, we present an overview of the different approaches taken across different companies (CROs, pharmaceutical/chemical companies, or other institutes) for sharing pathology material for educational and/or scientific purposes. The results of a survey and interviews with legal departments of different companies will be presented (anonymously) and discussed. In addition, the importance of sharing pathology data is addressed, as well as the challenges and opportunities this presents. Suggestions will be provided regarding what material should be made available and what will be needed to achieve agreement for this to happen.

共享病理数据对于教育和科学目的至关重要。由于大多数制药或(农)化学公司都将非临床安全性评估研究外包给合同研究组织 (CRO),因此这些研究的病理数据不归研究者所有,而是赞助这项工作的各公司的合法财产。尽管有些公司制定了管理病理数据共享的政策,但许多公司通常不允许基于合同研究组织的研究病理学家或赞助商病理学家将数据用于外部用途。管理外部使用数据的政策差异很大。本文概述了不同公司(CRO、制药/化学公司或其他机构)为教育和/或科研目的共享病理资料所采取的不同方法。我们将介绍(匿名)一项调查的结果,并与不同公司的法律部门进行访谈和讨论。此外,还将讨论共享病理资料的重要性以及由此带来的挑战和机遇。还将就哪些资料应予以提供以及为此达成一致所需的条件提出建议。
{"title":"Opinion on the Importance of Sharing Toxicologic Pathology Data for Educational and/or Scientific Purposes.","authors":"Eveline de Rijk, Phaedra Cole, Anna-Lena Frisk, Frederic Gervais, Joost Lensen, Barbara Lenz, Lars Mecklenburg, Flavia Pasello Dos Santos, Annette Romeike, Catherine Ross","doi":"10.1177/01926233241296122","DOIUrl":"10.1177/01926233241296122","url":null,"abstract":"<p><p>Sharing pathology data is critical for educational and scientific purposes. Since most pharmaceutical or (agro)chemical companies outsource nonclinical safety assessment studies to contract research organizations (CROs), the pathology data of those studies are not owned by the investigator but is the legal property of the respective company sponsoring the work. Although some companies have installed policies that govern sharing of pathology data, many companies generally do not allow the external use of data by either the CRO-based study pathologist or the sponsor pathologist. Policies for governing the external use of data vary significantly. In this article, we present an overview of the different approaches taken across different companies (CROs, pharmaceutical/chemical companies, or other institutes) for sharing pathology material for educational and/or scientific purposes. The results of a survey and interviews with legal departments of different companies will be presented (anonymously) and discussed. In addition, the importance of sharing pathology data is addressed, as well as the challenges and opportunities this presents. Suggestions will be provided regarding what material should be made available and what will be needed to achieve agreement for this to happen.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"1926233241296122"},"PeriodicalIF":1.4,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Historical Control Background Incidence of Spontaneous Nonneoplastic Lesions of Sprague Dawley Rats in 104-Week Carcinogenicity Studies. 在为期 104 周的致癌性研究中,Sprague Dawley 大鼠自发性非肿瘤性病变的历史控制背景发生率。
IF 1.4 4区 医学 Q3 PATHOLOGY Pub Date : 2024-10-29 DOI: 10.1177/01926233241289116
Marie Bockenstedt, Amit Kumar, Victoria Laast, Alok Sharma

Microscopic observation data collected from approximately 1800 male and female Sprague Dawley (SD) control rats used on 104-week carcinogenicity studies performed at North American Labcorp Early Development, Inc, Madison, WI, were retrospectively evaluated for spontaneous nonneoplastic findings. This study provides incidence of the most common spontaneous nonneoplastic microscopic findings in each organ system of SD rats encountered during 104-week carcinogenicity studies. Some of the most common spontaneous background findings were cardiomyopathy; chronic progressive nephropathy; uterine cystic endometrial hyperplasia; prostate inflammation; pulmonary alveolar macrophage infiltrates; hepatocyte vacuolation, bile duct hyperplasia, and basophilic foci in the liver; pancreatic fibrosis; splenic extramedullary hematopoiesis and pigment; decreased lymphocytes and epithelial hyperplasia in the thymus; ventral brain compression; cystic degeneration and hyperplasia of the adrenal cortex; and mammary gland hyperplasia. The most common nonneoplastic findings in male SD rats were chronic progressive nephropathy (80.9%) and rodent progressive cardiomyopathy (73.2%). The most common nonnenoplastic findings in female SD rats were cystic degeneration of the adrenal cortex (64.7%) and ventral compression of the brain due to pituitary neoplasms (62.7%).

在威斯康星州麦迪逊市的北美实验室早期开发公司(North American Labcorp Early Development, Inc)进行的为期 104 周的致癌性研究中,从约 1800 只雌雄 Sprague Dawley (SD) 对照组大鼠身上收集了显微镜观察数据,并对这些数据进行了回顾性评估,以确定是否存在自发性非肿瘤性结果。本研究提供了在 104 周致癌性研究期间 SD 大鼠各器官系统中最常见的自发性非肿瘤性显微镜检查结果的发生率。一些最常见的自发性背景发现包括心肌病、慢性进行性肾病、子宫囊性内膜增生、前列腺炎症、肺泡巨噬细胞浸润、肝细胞空泡化、胆管增生和肝脏嗜碱性病灶;胰腺纤维化;脾髓外造血和色素沉着;淋巴细胞减少和胸腺上皮增生;大脑腹侧受压;肾上腺皮质囊性变性和增生;乳腺增生。雄性 SD 大鼠最常见的非肿瘤性病变是慢性进行性肾病(80.9%)和啮齿动物进行性心肌病(73.2%)。雌性SD大鼠最常见的非肿瘤性病变是肾上腺皮质囊性变性(64.7%)和垂体肿瘤导致的大脑腹侧压迫(62.7%)。
{"title":"Historical Control Background Incidence of Spontaneous Nonneoplastic Lesions of Sprague Dawley Rats in 104-Week Carcinogenicity Studies.","authors":"Marie Bockenstedt, Amit Kumar, Victoria Laast, Alok Sharma","doi":"10.1177/01926233241289116","DOIUrl":"10.1177/01926233241289116","url":null,"abstract":"<p><p>Microscopic observation data collected from approximately 1800 male and female Sprague Dawley (SD) control rats used on 104-week carcinogenicity studies performed at North American Labcorp Early Development, Inc, Madison, WI, were retrospectively evaluated for spontaneous nonneoplastic findings. This study provides incidence of the most common spontaneous nonneoplastic microscopic findings in each organ system of SD rats encountered during 104-week carcinogenicity studies. Some of the most common spontaneous background findings were cardiomyopathy; chronic progressive nephropathy; uterine cystic endometrial hyperplasia; prostate inflammation; pulmonary alveolar macrophage infiltrates; hepatocyte vacuolation, bile duct hyperplasia, and basophilic foci in the liver; pancreatic fibrosis; splenic extramedullary hematopoiesis and pigment; decreased lymphocytes and epithelial hyperplasia in the thymus; ventral brain compression; cystic degeneration and hyperplasia of the adrenal cortex; and mammary gland hyperplasia. The most common nonneoplastic findings in male SD rats were chronic progressive nephropathy (80.9%) and rodent progressive cardiomyopathy (73.2%). The most common nonnenoplastic findings in female SD rats were cystic degeneration of the adrenal cortex (64.7%) and ventral compression of the brain due to pituitary neoplasms (62.7%).</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"1926233241289116"},"PeriodicalIF":1.4,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Toxicologic Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1